The drug is administered intramuscularly or intravenously. Standard dosing regimen
Adults and children over 12 years of age: for 1-2 g once a day (every 24 hours). In severe cases or infections, the causative agents of which have only moderate sensitivity to ceftriaxone, the daily dose can be increased to 4 g.
Newborns (up to 2 weeks): 20-50 mg / kg body weight once a day. The daily dose should not exceed 50 mg / kg of body weight. When determining the dose, there is no need to distinguish between full and premature babies.
Infants and young children (from 15 days to 12 years): 20-80 mg / kg body weight once a day.
Children with a body weight above 50 kg are prescribed doses for adults.
Intravenous doses of 50 mg / kg or higher should be administered drip for at least 30 minutes.
Patients of senile age: usual doses for adults, without adjustments for age. Duration of treatment depends on the course of the disease.As always with antibiotic therapy, Ceftriaxone-Vial should be continued for at least 48-72 hours after the temperature is normalized and the eradication of the pathogen is confirmed.
Dosing in special cases
When bacterial meningitis in infants and young children treatment starts with a dose of 100 mg / kg (but not more than 4 g) 1 time per day. After identifying the pathogen and determining its sensitivity, the dose can be reduced accordingly. The best results with meningococcal meningitis were achieved with a treatment duration of 4 days, with meningitis caused by Haemophilus influenzae - 6 days, Streptococcus pneumoniae - 7 days. Borrelia Lyme: 50 mg / kg (the highest daily dose is 2 g) for adults and children over 12 years of age once a day for 14 days.
Gonorrhea (caused by penicillinase-forming and penicillin-zoned strains): single intramuscular injection of 250 mg Ceftriaxone-Vial.
Prevention of postoperative infections, depending on the degree of infectious risk, 1-2 g of Ceftriaxone-Vial is administered once 30-90 minutes before the operation. In operations on the colon and rectum, the simultaneous (but separate) administration of Ceftriaxone-Vial and one of the 5-nitroimidazoles, for example, ornidazole, was well established.In patients with impaired renal function there is no need to reduce the dose, if the function liver remains normal. The daily dose of the drug should not exceed 2 g only in cases of preterminal renal failure (creatinine clearance less than 10 ml / min). In patients with hepatic dysfunction there is no need to reduce the dose, if the function kidneys remains normal.
When combination of severe renal and hepatic insufficiency should regularly determine the concentration of ceftriaxone in the plasma and, if necessary, adjust its dose. Patients on dialysis additional introduction of the drug after dialysis is not required. It should, however, control the concentration of ceftriaxone in the serum for possible dose adjustment, since the rate of excretion of the drug in these patients may be reduced.
Mode of application
For intramuscular injection: The contents of the vial are dissolved as follows:
Contents of the bottle Solvent (water for injection)
1 g 3.6 ml
After preparation, each 1 ml of the solution contains about 250 mg in terms of ceftriaxone.
If necessary, a more dilute solution may be used.As with other intramuscular injections, Ceftriaxone-Vial is injected into a relatively large muscle; Trial aspiration helps to avoid unintentional insertion into the blood vessel. It is recommended to inject no more than 1000 mg of the drug into one buttock. To reduce pain with intramuscular injections, the drug should be administered with a 1% solution of lidocaine (intragenic). Do not inject lidocaine solution intravenously.
For intravenous administration: The contents of the vial are dissolved as follows:
Contents of the bottle Solvent (water for injection)
1 g 9.6 ml
After preparation, each 1 ml of the solution contains about 100 mg in terms of ceftriaxone. The solution is administered slowly for 2-4 minutes.
For intravenous infusion dissolve 2 g of Ceftriaxone-Vial in 40 ml of sterile water for injection or one of the infusion solutions that do not contain calcium (0.9% sodium chloride solution, 2.5%, 5% or 10% dextrose solution, 5% levulose solution, 6 % dextran solution in dextrose). The solution is introduced for 30 minutes.